花旗发表研报指，药明合联将2025财年收入增长指引由逾35%上调至逾45%，该行认为新指引仍然较保守。管理层同时预期2025年毛利率将高于2024年，基于产能利用率提升，但下半年毛利率将低于上半年，因有更多维护成本及设施更新支出。该行将2025至27年收入预测分别上调6%、8%及8%，反映强劲的项目交付及订单增长；因毛利率预期提升，每股盈利预测分别上调18%、21%及22%。该行将其目标价由46港元上调至70港元，评级“买入”，未来十年收入的年均复合增长率预测亦由23%上调至26%。
花旗发表研报指，药明合联将2025财年收入增长指引由逾35%上调至逾45%，该行认为新指引仍然较保守。管理层同时预期2025年毛利率将高于2024年，基于产能利用率提升，但下半年毛利率将低于上半年，因有更多维护成本及设施更新支出。该行将2025至27年收入预测分别上调6%、8%及8%，反映强劲的项目交付及订单增长；因毛利率预期提升，每股盈利预测分别上调18%、21%及22%。该行将其目标价由46港元上调至70港元，评级“买入”，未来十年收入的年均复合增长率预测亦由23%上调至26%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.